

PRESS RELEASE
15 April 2014



This press release may not be published or distributed, directly or indirectly in or into the United States, or any other jurisdiction where such action is subject to legal restrictions.

Information regarding on-going new share issues

The rights issue in BioInvent of MSEK 48.9, with preferential rights for the company's shareholders, has been oversubscribed. The subscription period ended on 11 April 2014. Approx. 95 per cent of the shares offered have been subscribed for with subscription rights and in total notifications to subscribe for shares without subscriptions rights have been received corresponding to 101 per cent of the shares offered.

Due to an administrative error with the Custodial bank, the Company's largest shareholder Van Herk Investments B.V. has sold subscription rights corresponding to 3,193,312 shares instead of exercising these in accordance with the subscription undertaking. Van Herk Investments B.V. has in writing to the Company undertaken to in a supervised manner purchase the equivalent number of shares in the market during a period estimated to amount to about sixty trading days and informed that Van Herk Investments B.V. will announce to the market when the share purchase is completed. Due to this occurrence an addendum prospectus will be prepared which is estimated to be published prior to the Stock Exchange opening on Thursday 17 April 2014 together with information about the final outcome of the rights issue. The Company deems that the previously announced timetable for registration of the new share issues and admission to trading will not be effected.

Advisors

Erik Penser Bankaktiebolag is acting as financial advisor and Mannheimer Swartling Advokatbyrå AB is acting as legal advisor to BioInvent in connection to the new share issues.

-- END --

To the editors:

About BioInvent

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR[®] are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and Mitsubishi Tanabe Pharma. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

info@bioinvent.com

www.bioinvent.com

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent. Any invitation to the persons concerned to subscribe for shares in BioInvent will only be made through the prospectus that BioInvent published on 25 March 2014.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect BioInvent's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 6.00 p.m. CET, on 15 April, 2014.